JENKINTOWN, PA — SFA Therapeutics, Inc. has named James Kirwin, MBA, as its new Chief Operating Officer. Kirwin will spearhead clinical trial agreements, oversee collaborations with regulatory teams, and manage the development of clinical trial materials.
Kirwin brings over 20 years of experience in biopharmaceutical clinical operations. His background includes roles in both global pharmaceutical companies and biotech startups. His expertise spans research and development, pre-clinical and clinical asset management, and leading high-performing teams.
“As we advance SFA-002 and other candidates through the clinic, Jim will be crucial in managing Clinical Development Operations,” said Dr. Ira Spector, CEO of SFA Therapeutics. “Jim’s ability to execute strategy with cross-functional teams will drive organizational excellence.”
Kirwin expressed his enthusiasm about his new role, saying, “I look forward to applying my clinical operations skills to develop industry-leading operations. SFA Therapeutics’ novel platform can tailor biosynthetic compounds, and I am excited to help drive this science through the clinic.”
Kirwin previously served as Executive Director at Arvinas, where he built the clinical operations organization and initiated programs for breast and prostate cancer. He also worked at Iterum Therapeutics, overseeing a global clinical trial program. His career includes senior roles at Intercept Pharmaceuticals, Taiho Oncology, Medtronic Spine and Biologics, Intrexon Corporation, Pfizer, Wyeth Pharmaceuticals, and AstraZeneca.
Kirwin holds a degree in Microbiology and Molecular Biology from Pennsylvania State University and an MBA from the University of Delaware.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.